Abstract
Despite numerous remarkable achievements in a variety of complex challenges,1, 2 standalone artificial intelligence (AI) does not unlock life science from the long-term bottleneck of linearly extracting new knowledge from exponentially growing new data3 that severely limits the clinical success rate of drug discovery.4 Inspired by state-of-the-art AI training methods, we propose a human-centric augmented intelligence5 (HAI) to learn a foundation model6 that extracts all-encompassing knowledge of human physiology and diseases. To evaluate the quality of HAI’s extracted knowledge, a real-world validation— the public, prospective prediction of pivotal ongoing clinical trial success outcomes at large scale (PROTOCOLS)—was also developed to benchmark HAI’s performance with experts’ baseline in the prospective prediction sensitivity of successful clinical programs with only preclinical data as inputs. HAI achieved a 11.4-fold improvement from the baseline with a 99% confidence7 in the PROTOCOLS validation. The decision-support integration of HAI at the stage of selecting development candidates to enter first-in-human studies could significantly increase the average clinical success rate of investigational new drugs from 7.9%8 to 90.1% for nearly any disease.9, 10 This result confirms that exponentially extracted knowledge alone may be sufficient to accurately predict clinical success, effecting a complete reversal of Eroom’s law.4 The trained HAI is also the world’s first clinically validated model of human aging that could substantially speed up the discovery of preventive medicine for all age-related diseases.11 This study demonstrates that disruptive breakthroughs necessitate the smallest team size to attain the largest HAI for optimal knowledge extraction from high-dimensional, low-quality data spaces, thus establishing the first prospective proof of the previous discovery that small teams disrupt12. The global adoption of training HAI may provide a new path to mass producing scientific and technological breakthroughs via exponential knowledge extraction and better designs of data labels for training better-performing AI.13
Competing Interest Statement
This study was funded by Demiurge Technologies AG. B.L. and I.L. are employees, board members, and shareholders of Demiurge Technologies AG.
Funding Statement
This study did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Manuscript revised; Methods added; Typos corrected;
Data Availability
All data produced in the present study are available upon reasonable request to the authors.